2023.12.16
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, stock code: 02315.HK) recently announced that it had entered into evaluation, option and license and/or transfer agreements with multiple overseas biopharmaceutical companies, including Pheon Therapeutics, Myricx Bio, Ona Therapeutics and Neurocrine Biosciences (the “Licensees”), respectively.
Under these agreements, Biocytogen will provide fully human antibodies developed using its proprietary mice platforms to the Licensees for evaluation and grant the Licensees an option to acquire a worldwide license in respect of the subsequent development, manufacturing and commercialization of the selected antibodies. Biocytogen will receive an upfront payment, an option exercise fee, ongoing development and commercialization milestone payments, as well as royalties on net sales.
Biocytogen is a global biotechnology company that drives the research and development of novel drugs with innovative technologies. The company has developed its own RenMice® (RenMab®, RenLite®, RenNano® and RenTCR-mimicTM) platforms based on underlying gene editing technology, for the discovery of fully human therapeutic monoclonal antibodies, bispecific/multispecific antibodies, bispecific antibody-drug conjugates (bsADCs), nanobodies, and TCRm antibodies.
Among those Licensees, Pheon Therapeutics is a U.K. ADC specialist developing a pipeline of monotherapies for novel targets and/or with novel payloads; Myricx Bio is a U.K. biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for ADCs; Ona Therapeutics is a Spanish biotech company that specializes in unravelling novel biology to design first-in-class biopharmaceuticals that attack advanced cancer; and Neurocrine Biosciences is a U.S. biopharmaceutical company committed to the discovery and development of therapies for neurological, neuroendocrine and neuropsychiatric diseases.
JunHe was engaged by Biocytogen to draft, review, negotiate and revise the transaction documents. With its consistent delivery of efficient and rigorous legal services and detail-oriented and professional expertise, JunHe’s team was highly recognized by the client.
The JunHe team was led by partner ZHAO, Hao (Gerry).
